Press Room

News / Oct 08, 2019

Celebrating our 60th Anniversary in Cork

10 years in Cork, 60 years in the world.

On September 5th 2019, Hovione celebrated its 60th anniversary at the Cork site in Ireland.

The event joined together team members, clients and stakeholders that make Hovione a great Company.

Guy Villax Simon Coveney Manufacturing Plant Ringaskiddy Cork, Ireland | Hovione
Guy Villax and Simon Coveney, Tánaiste and Minister for Foreign Affairs and Trade of Ireland

 

“I’m delighted to see the Cork site playing such an important part in the success of this impressive company,” said Simon Coveney TD, Tánaiste and Minister for Foreign Affairs and Trade speaking at the celebration event for Hovione’s 60th anniversary.

“Hovione has seen steady growth over the last few years and I’m confident that the coming years will be equally successful for the Cork team.”

 

60th Anniversary in Cork | Hovione
Paul Downing and Simon Coveney, Tánaiste and Minister for Foreign Affairs and Trade of Ireland

 

Celebrating 60th Anniversary in Cork | Hovione
Photo Group
60th Anniversary in Cork | Hovione
Ambassador of Portugal in Ireland, Miguel de Almeida e Sousa, Guy Villax and Paul Downing

 

“Our Cork site plays a significant and strategic role within the Hovione network,” said Hovione CEO, Guy Villax. “With two Active Pharmaceutical Ingredient facilities alongside a Drug Product Intermediate facility that houses the largest commercial pharmaceutical spray dryer in operation, the Cork site boasts both extensive manufacturing capacity and people capability.”

 

Guy Villax Paul Downing at Manufacturing Plant in Cork Ireland | Hovione
Guy Villax, Paul Downing and a Cork tree from Portugal in Cork

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026